Fate Therapeutics, Inc. fell 16.8% on Thursday, November 12, 2026, on 3,685,100 shares, 2.5 times its average daily volume. No headline about FATE came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Fate Therapeutics, Inc. (FATE:NASDAQ) closed at $1.28 on November 13, 2026, down 4.48% on the day. The stock trades 60.4% below its 52-week high of $3.23 and 34.7% above its 52-week low of $0.950. Over the past year, it gained 33.3%. Fate Therapeutics, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since November 13, 2025, FATE closed higher on 118 days (47%). Its best day was May 5, 2026 (+31.11%) and its worst was November 12, 2026 (-16.77%). The stock moved 10% or more in a single session 18 times. It opened at least 5% above the previous day's high 1 time.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators...
Find more stocks like FATE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.